Literature DB >> 23464335

Development of MRI phantom equivalent to human tissues for 3.0-T MRI.

Kengo Hattori1, Yusuke Ikemoto, Wataru Takao, Seiichiro Ohno, Takashi Harimoto, Susumu Kanazawa, Masataka Oita, Koichi Shibuya, Masahiro Kuroda, Hirokazu Kato.   

Abstract

PURPOSE: A 3.0-T MRI phantom (called the CAGN-3.0T phantom) having human-equivalent relaxation times and human-equivalent conductivity was developed.
METHODS: The ingredients of the phantom are carrageenan (as a gelatinizer), agarose (as a T2-relaxation modifier), GdCl3 (as a T1-relaxation modifier), NaCl (as a conductivity modifier), and NaN3 (as an antiseptic). Numerous samples with varying concentrations of agarose, GdCl3, and NaCl were prepared, and T1 and T2 values were measured using 3.0-T MRI.
RESULTS: The T1 values of the CAGN-3.0T phantom were unaffected by NaCl, while the T2 values were only slightly affected. Based on the measured data, empirical formulae were devised to express the relationships between the concentrations of agarose, GdCl3, and NaCl and the relaxation times. The formula for expressing the conductivity of the CAGN-3.0T phantom was obtained.
CONCLUSIONS: By adjustments to the concentrations of agarose, GdCl3, and NaCl, the relaxation times and conductivity of almost all types of human tissues can be simulated by CAGN-3.0T phantoms. The phantoms have T1 values of 395-2601 ms, T2 values of 29-334 ms, and conductivity of 0.27-1.26 S/m when concentrations of agarose, GdCl3, and NaCl are varied from 0 to 2.0 w/w%, 0 to 180 μmol/kg, and 0 to 0.7 w/w%, respectively. The CAGN-3.0T phantom has sufficient strength to replicate the torso without using reinforcing agents, and can be cut with a knife into any shape.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23464335     DOI: 10.1118/1.4790023

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  7 in total

1.  Fluid assessment in dialysis patients by point-of-care magnetic relaxometry.

Authors:  Lina A Colucci; Kristin M Corapi; Matthew Li; Xavier Vela Parada; Andrew S Allegretti; Herbert Y Lin; Dennis A Ausiello; Matthew S Rosen; Michael J Cima
Journal:  Sci Transl Med       Date:  2019-07-24       Impact factor: 17.956

2.  Bilateral Changes in Deep Tissue Environment After Manual Lymphatic Drainage in Patients with Breast Cancer Treatment-Related Lymphedema.

Authors:  Paula M C Donahue; Rachelle Crescenzi; Allison O Scott; Vaughn Braxton; Aditi Desai; Seth A Smith; John Jordi; Ingrid M Meszoely; Ana M Grau; Rondi M Kauffmann; Raeshell S Sweeting; Kandace Spotanski; Sheila H Ridner; Manus J Donahue
Journal:  Lymphat Res Biol       Date:  2017-03       Impact factor: 2.589

Review 3.  Anthropomorphic brain phantoms for use in MRI systems: a systematic review.

Authors:  Noelle Crasto; Abirami Kirubarajan; Dafna Sussman
Journal:  MAGMA       Date:  2021-08-31       Impact factor: 2.310

4.  Optimal Experiment Design for Magnetic Resonance Fingerprinting: Cramér-Rao Bound Meets Spin Dynamics.

Authors:  Justin P Haldar; Mark A Griswold; Kawin Setsompop; Lawrence L Wald
Journal:  IEEE Trans Med Imaging       Date:  2018-10-04       Impact factor: 10.048

5.  Characterization of 3D printing techniques: Toward patient specific quality assurance spine-shaped phantom for stereotactic body radiation therapy.

Authors:  Min-Joo Kim; Seu-Ran Lee; Min-Young Lee; Jason W Sohn; Hyong Geon Yun; Joon Yong Choi; Sang Won Jeon; Tae Suk Suh
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

6.  Soft 3D-Printed Phantom of the Human Kidney with Collecting System.

Authors:  Fabian Adams; Tian Qiu; Andrew Mark; Benjamin Fritz; Lena Kramer; Daniel Schlager; Ulrich Wetterauer; Arkadiusz Miernik; Peer Fischer
Journal:  Ann Biomed Eng       Date:  2016-11-09       Impact factor: 3.934

Review 7.  Recent advances on the development of phantoms using 3D printing for imaging with CT, MRI, PET, SPECT, and ultrasound.

Authors:  Valeria Filippou; Charalampos Tsoumpas
Journal:  Med Phys       Date:  2018-06-22       Impact factor: 4.071

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.